THOMAS SCIASCIA - 19 Feb 2026 Form 4 Insider Report for Trevi Therapeutics, Inc. (TRVI)

Role
Chief Scientific Officer
Signature
/s/ Christopher Galletta, attorney-in-fact
Issuer symbol
TRVI
Transactions as of
19 Feb 2026
Net transactions value
$0
Form type
4
Filing time
20 Feb 2026, 16:16:27 UTC
Previous filing
03 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
SCIASCIA THOMAS Chief Scientific Officer C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, 16TH FLOOR, NEW HAVEN /s/ Christopher Galletta, attorney-in-fact 20 Feb 2026 0001229946

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRVI Stock Option (right to buy) Award $0 +85,000 $0.000000 85,000 19 Feb 2026 Common Stock 85,000 $10.56 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on February 19, 2026. The 85,000 shares of common stock underlying the option are scheduled to vest in equal monthly installments through February 19, 2030, subject to the reporting person's continued service with the issuer.